Spots Global Cancer Trial Database for Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction
Official Title: A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Study ID: NCT02070549
Interventions
Study Description
Brief Summary: This phase I trial studies the side effects and best dose of trametinib in treating patients with cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) with or without liver (hepatic) dysfunction. Trametinib may stop the growth of tumor cells by blocking proteins needed for cell growth. When these proteins are blocked, the growth of cancer cells may be stopped and the cancer cells will then die. Hepatic dysfunction is frequently found in patients with advanced cancer and usually prevents patients from receiving standard treatments or from participating in clinical trials. Patients may also need dose adjustments or absorb drugs differently. Trametinib may be a better treatment for patients with advanced cancers and hepatic dysfunction.
Detailed Description: PRIMARY OBJECTIVES: I. To provide appropriate dosing recommendations for patients with varying degree of hepatic dysfunction receiving trametinib (mild, moderate and severe). II. To establish the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of trametinib in advanced cancer patients with varying degrees of hepatic dysfunction. III. To characterize the pharmacokinetic (PK) profile of trametinib in advanced cancer patients with varying degrees of hepatic dysfunction. SECONDARY OBJECTIVES: I. To document the non-DLTs associated with the administration of trametinib in patients with varying degrees of hepatic dysfunction. II. To document any antitumor activity associated with trametinib treatment of patients enrolled on this study. III. To explore and characterize predictive biomarkers for individual cancer patients utilizing genomic sequencing technologies. OUTLINE: This is a dose-escalation study. Patients receive trametinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 4 weeks.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Moffitt Cancer Center, Tampa, Florida, United States
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
M D Anderson Cancer Center, Houston, Texas, United States
BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
Contact Details
Name: Lillian L Siu
Affiliation: University Health Network Princess Margaret Cancer Center LAO
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
